DPP4 and urogenital neoplasm: Recently, a 3-month clinical trial of vildagliptin, another oral DPP-4 inhibitor, revealed that this agent improved oral glucose tolerance test outcomes and modestly improved hemoglobin A1c in kidney transplant recipients with impaired glucose tolerance (IGT) [14].